Breaking News

Financial Report: PAREXEL

August 7, 2014

Revenues up 11% in the quarter

PAREXEL

4Q Revenues: $585.1 million (+11%)

4Q Earnings: $40.1 million (+34%)

FY Revenues: $2.3 billion (+14%)

FY Earnings: $129.1 million (+34%)

Comments: Consolidated service revenue increased 10% in the quarter to $510.6 million, with $385.6 million in Clinical Research Services (CRS), $55.2 million in PAREXEL Consulting (PC), and $69.8 million in PAREXEL Informatics (PI). For the year consolidated service revenue was up 12% to $1.9 billion, with $1.5 billion in CRS, $216.2 million in PC, and $267.9 million in PAREXEL Informatics, Inc.The recent acquisition of the HERON Group contributed approximately $3.8 million in the quarter, and contributed $2.2 million for the fiscal year. Backlog at the end of June 2014 was $5.0 billion, up 9% for the year.
blog comments powered by Disqus
  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture

  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments